233 related articles for article (PubMed ID: 31093891)
21. Potential using of microRNA-34A in combination with paclitaxel in colorectal cancer cells.
Soltani-Sedeh H; Irani S; Mirfakhraie R; Soleimani M
J Cancer Res Ther; 2019; 15(1):32-37. PubMed ID: 30880751
[TBL] [Abstract][Full Text] [Related]
22. Micellar Delivery of miR-34a Modulator Rubone and Paclitaxel in Resistant Prostate Cancer.
Wen D; Peng Y; Lin F; Singh RK; Mahato RI
Cancer Res; 2017 Jun; 77(12):3244-3254. PubMed ID: 28428276
[TBL] [Abstract][Full Text] [Related]
23. Emodin enhances antitumor effect of paclitaxel on human non-small-cell lung cancer cells in vitro and in vivo.
Chen S; Zhang Z; Zhang J
Drug Des Devel Ther; 2019; 13():1145-1153. PubMed ID: 31114158
[No Abstract] [Full Text] [Related]
24. Polymeric Hybrid Nanomicelles for Cancer Theranostics: An Efficient and Precise Anticancer Strategy for the Codelivery of Doxorubicin/miR-34a and Magnetic Resonance Imaging.
Xie X; Chen Y; Chen Z; Feng Y; Wang J; Li T; Li S; Qin X; Wu C; Zheng C; Zhu J; You F; Liu Y; Yang H
ACS Appl Mater Interfaces; 2019 Nov; 11(47):43865-43878. PubMed ID: 31684723
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic Ultrasound Contrast Agents for the Enhancement of Tumor Diagnosis and Tumor Therapy.
Moon H; Yoon C; Lee TW; Ha KS; Chang JH; Song TK; Kim K; Kim H
J Biomed Nanotechnol; 2015 Jul; 11(7):1183-92. PubMed ID: 26307841
[TBL] [Abstract][Full Text] [Related]
26. HeLa Cell-Derived Paclitaxel-Loaded Microparticles Efficiently Inhibit the Growth of Cervical Carcinoma.
Peng J; Zhao J; Zhao Y; Wu P; Gou L; Fu S; Chen P; Lu Y; Yang L
Int J Nanomedicine; 2020; 15():6409-6420. PubMed ID: 32922008
[TBL] [Abstract][Full Text] [Related]
27. Preparation Of Nanobubbles Modified With A Small-Molecule CXCR4 Antagonist For Targeted Drug Delivery To Tumors And Enhanced Ultrasound Molecular Imaging.
Peng Y; Zhu L; Wang L; Liu Y; Fang K; Lan M; Shen D; Liu D; Yu Z; Guo Y
Int J Nanomedicine; 2019; 14():9139-9157. PubMed ID: 32063704
[TBL] [Abstract][Full Text] [Related]
28. Polymeric Nanomedicine for Combined Gene/Chemotherapy Elicits Enhanced Tumor Suppression.
Xu B; Xia S; Wang F; Jin Q; Yu T; He L; Chen Y; Liu Y; Li S; Tan X; Ren K; Yao S; Zeng J; Song X
Mol Pharm; 2016 Feb; 13(2):663-76. PubMed ID: 26695934
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic ultrasonic microbubbles carrying paclitaxel and LyP-1 peptide: preparation, characterization and application to ultrasound-assisted chemotherapy in breast cancer cells.
Yan F; Li X; Jin Q; Jiang C; Zhang Z; Ling T; Qiu B; Zheng H
Ultrasound Med Biol; 2011 May; 37(5):768-79. PubMed ID: 21458148
[TBL] [Abstract][Full Text] [Related]
30. JD enhances the anti-tumour effects of low-dose paclitaxel on gastric cancer MKN45 cells both in vitro and in vivo.
Wang C; Wang R; Zhou K; Wang S; Wang J; Shi H; Dou Y; Yang D; Chang L; Shi X; Liu Y; Xu X; Zhang X; Ke Y; Liu H
Cancer Chemother Pharmacol; 2016 Nov; 78(5):971-982. PubMed ID: 27620208
[TBL] [Abstract][Full Text] [Related]
31. miR-21 inhibitor suppresses cell proliferation and colony formation through regulating the PTEN/AKT pathway and improves paclitaxel sensitivity in cervical cancer cells.
Du G; Cao D; Meng L
Mol Med Rep; 2017 May; 15(5):2713-2719. PubMed ID: 28447761
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA 100 sensitizes luminal A breast cancer cells to paclitaxel treatment in part by targeting mTOR.
Zhang B; Zhao R; He Y; Fu X; Fu L; Zhu Z; Fu L; Dong JT
Oncotarget; 2016 Feb; 7(5):5702-14. PubMed ID: 26744318
[TBL] [Abstract][Full Text] [Related]
33. Paclitaxel-liposome-microbubble complexes as ultrasound-triggered therapeutic drug delivery carriers.
Yan F; Li L; Deng Z; Jin Q; Chen J; Yang W; Yeh CK; Wu J; Shandas R; Liu X; Zheng H
J Control Release; 2013 Mar; 166(3):246-55. PubMed ID: 23306023
[TBL] [Abstract][Full Text] [Related]
34. Improved anti-tumor efficacy of paclitaxel in combination with MicroRNA-125b-based tumor-associated macrophage repolarization in epithelial ovarian cancer.
Parayath NN; Gandham SK; Leslie F; Amiji MM
Cancer Lett; 2019 Oct; 461():1-9. PubMed ID: 31288064
[TBL] [Abstract][Full Text] [Related]
35. Long noncoding RNA CASC2 promotes paclitaxel resistance in breast cancer through regulation of miR-18a-5p/CDK19.
Zheng P; Dong L; Zhang B; Dai J; Zhang Y; Wang Y; Qin S
Histochem Cell Biol; 2019 Oct; 152(4):281-291. PubMed ID: 31352515
[TBL] [Abstract][Full Text] [Related]
36. Study of the UTMD-based delivery system to induce cervical cancer cell apoptosis and inhibit proliferation with shRNA targeting Survivin.
Chen ZY; Liang K; Lin Y; Yang F
Int J Mol Sci; 2013 Jan; 14(1):1763-77. PubMed ID: 23325045
[TBL] [Abstract][Full Text] [Related]
37. miR-375 is upregulated in acquired paclitaxel resistance in cervical cancer.
Shen Y; Wang P; Li Y; Ye F; Wang F; Wan X; Cheng X; Lu W; Xie X
Br J Cancer; 2013 Jul; 109(1):92-9. PubMed ID: 23778521
[TBL] [Abstract][Full Text] [Related]
38. Combination therapy with bioengineered miR-34a prodrug and doxorubicin synergistically suppresses osteosarcoma growth.
Zhao Y; Tu MJ; Yu YF; Wang WP; Chen QX; Qiu JX; Yu AX; Yu AM
Biochem Pharmacol; 2015 Dec; 98(4):602-13. PubMed ID: 26518752
[TBL] [Abstract][Full Text] [Related]
39. MiR-34a Inhibits Viability and Invasion of Human Papillomavirus-Positive Cervical Cancer Cells by Targeting E2F3 and Regulating Survivin.
Geng D; Song X; Ning F; Song Q; Yin H
Int J Gynecol Cancer; 2015 May; 25(4):707-13. PubMed ID: 25675046
[TBL] [Abstract][Full Text] [Related]
40. Paclitaxel-loaded N-octyl-O-sulfate chitosan micelles for superior cancer therapeutic efficacy and overcoming drug resistance.
Jin X; Mo R; Ding Y; Zheng W; Zhang C
Mol Pharm; 2014 Jan; 11(1):145-57. PubMed ID: 24261922
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]